UTP4 Antibody

Basic Research Questions

• What is UTP4/Cirhin and what is its function in cellular processes?

UTP4/Cirhin functions as a crucial ribosome biogenesis factor involved in the nucleolar processing of pre-18S ribosomal RNA. It serves as a component of the small subunit (SSU) processome, which is the first precursor of the small eukaryotic ribosomal subunit . During SSU processome assembly in the nucleolus, UTP4 works alongside numerous other ribosome biogenesis factors, RNA chaperones, and ribosomal proteins to facilitate RNA folding, modifications, rearrangements, and cleavage processes essential for ribosome maturation .

More specifically, UTP4 is involved in SSU pre-rRNA processing at sites A', A0, 1, and 2b, and is required for optimal pre-ribosomal RNA transcription by RNA polymerase . Research has also indicated that UTP4 may function as a transcriptional regulator . The t-Utp subcomplex, which includes UTP4, has been demonstrated to be necessary for both rDNA transcription and pre-rRNA processing .

The clinical significance of UTP4 is highlighted by the discovery that a missense mutation in the C-terminus of human Utp4/Cirhin causes North American Indian childhood cirrhosis (NAIC), an autosomal recessive form of familial cholestasis that progresses to biliary cirrhosis requiring liver transplantation in childhood or adolescence . The NAIC mutation results in the substitution of tryptophan for arginine at position 565 of Utp4/Cirhin .

• What are the recommended protocols for using UTP4 antibodies in immunocytochemistry/immunofluorescence?

For optimal results when using UTP4 antibodies in immunofluorescence experiments, researchers should follow this systematic protocol:

Sample Preparation:

• Culture cells on sterile coverslips or chamber slides until they reach 70-80% confluence.

• Fix cells using 4% paraformaldehyde in PBS for 15 minutes at room temperature.

• Permeabilize cells with 0.2% Triton X-100 in PBS for 10 minutes.

• Block non-specific binding sites with 5% normal serum (from the species of secondary antibody origin) in PBS containing 0.1% Tween-20 for 1 hour at room temperature.

Antibody Incubation:

• Dilute the primary UTP4/Cirhin antibody (such as ab220326) at a concentration of 1:100 to 1:500 in blocking buffer .

• Incubate cells with the diluted primary antibody overnight at 4°C in a humidified chamber.

• Wash cells 3-5 times with PBS containing 0.1% Tween-20.

• Incubate with an appropriate fluorophore-conjugated secondary antibody at a concentration of 1:500 to 1:1000 for 1-2 hours at room temperature in the dark.

• Wash cells 3-5 times with PBS containing 0.1% Tween-20.

• Counterstain nuclei with DAPI (1 μg/ml) for 5 minutes.

• Mount slides using an anti-fade mounting medium.

Imaging Considerations:

• Since UTP4/Cirhin is primarily localized to the nucleolus, confocal microscopy is recommended for detailed visualization of its subnuclear distribution .

• Include appropriate controls, such as a negative control omitting the primary antibody and a positive control using cells known to express UTP4.

• For co-localization studies, consider using markers for nucleolar structures such as fibrillarin or nucleolin to confirm the expected localization pattern.

Optimization Tips:

• The optimal dilution of the UTP4 antibody should be determined empirically for each application and cell type.

• If high background is observed, increase the number or duration of washing steps or try a more stringent blocking buffer.

• For fixed tissues, longer antibody incubation times or slightly higher concentrations may be required compared to cultured cells.

• How should UTP4 antibodies be stored and handled for optimal results?

Proper storage and handling of UTP4 antibodies are critical for maintaining their specificity and activity over time. Following these guidelines will help preserve antibody performance:

Storage Conditions:

• Store UTP4 antibodies at -20°C for long-term storage, with aliquoting recommended to avoid freeze-thaw cycles.

• For short-term storage (up to one month), antibodies can be kept at 4°C.

• Avoid repeated freeze-thaw cycles, as these can lead to protein denaturation and loss of antibody activity.

• For working solutions, store at 4°C and use within 1-2 weeks.

Handling Guidelines:

• Always centrifuge antibody vials briefly before opening to collect the solution at the bottom of the tube.

• Use sterile techniques when handling antibody solutions to prevent microbial contamination.

• When diluting antibodies, use high-quality, filtered buffers prepared with ultrapure water.

• For dilution, use appropriate buffers such as PBS with 0.1% BSA or 5% normal serum that matches the host species of the secondary antibody.

• When preparing aliquots, use sterile tubes and minimize the time the stock solution is exposed to room temperature.

• Never vortex antibody solutions; instead, mix by gentle inversion or flicking to prevent antibody denaturation.

Stabilization and Recovery:

• If activity decreases over time, adding BSA (0.1-1%) or glycerol (30-50%) to the antibody solution can help stabilize it.

• If precipitation occurs, centrifuge the antibody solution and use the supernatant.

• For antibodies that show reduced activity after storage, sometimes activity can be partially restored by incubating at 37°C for 30-60 minutes.

Quality Control:

• Keep detailed records of antibody lot numbers, receipt dates, and performance in experiments.

• Perform periodic quality control tests on stored antibodies to ensure they maintain their specificity and sensitivity.

• Consider including a positive control in each experiment to verify that the antibody is working as expected.

• What are the known cross-reactivity issues with UTP4 antibodies?

Understanding potential cross-reactivity is essential when working with UTP4 antibodies to ensure accurate interpretation of experimental results. This is particularly important given UTP4's role in complex nucleolar structures and protein interactions.

Known Cross-Reactivity Patterns:

Potential Sources of Cross-Reactivity:

• Structural Homologs: UTP4/Cirhin shares structural features with other proteins involved in RNA processing, which may lead to cross-reactivity.

• Conserved Domains: The functional domains of UTP4 may be conserved across different proteins involved in ribosome biogenesis.

• Species Conservation: While human and yeast Utp4 are orthologs, they show limited sequence conservation, which affects antibody cross-species reactivity .

Minimizing Cross-Reactivity Issues:

• Antibody Validation: Always validate antibodies using appropriate positive and negative controls, including knockout or knockdown samples when possible.

• Blocking Optimization: Adjust blocking conditions to reduce non-specific binding. Try different blocking agents such as BSA, normal serum, or commercial blocking buffers.

• Absorption Controls: Pre-absorb antibodies with recombinant antigen to confirm specificity.

• Secondary Antibody Selection: Choose secondary antibodies with minimal cross-reactivity to the species being studied.

• Dilution Optimization: Titrate antibody concentrations to find the optimal balance between specific signal and background.

Application-Specific Considerations:

• Western Blotting: Include multiple controls and verify band size corresponds to the predicted molecular weight of UTP4 (approximately 76 kDa for human UTP4).

• Immunofluorescence: Compare staining patterns with known nucleolar markers to confirm the expected subcellular localization.

• Immunoprecipitation: Validate pull-downs using mass spectrometry or known interacting partners of UTP4.

• What applications are most appropriate for UTP4 antibodies in basic research?

UTP4 antibodies are valuable tools for investigating various aspects of ribosome biogenesis, nucleolar function, and related disease mechanisms. Based on current research, the following applications have proven most effective:

Immunocytochemistry/Immunofluorescence (ICC/IF):
UTP4 antibodies have been specifically validated for ICC/IF applications to visualize the subcellular localization of UTP4/Cirhin, particularly in the nucleolus . This technique allows researchers to observe UTP4 distribution patterns and potential colocalization with other nucleolar components. The nucleolar localization pattern serves as an important control for antibody specificity, as UTP4 has been consistently shown to concentrate in nucleoli across multiple studies .

Immunoprecipitation (IP):
Studies using yeast Utp4 have demonstrated the utility of antibodies against tagged versions of UTP4 in immunoprecipitation assays to analyze protein-protein interactions within the SSU processome complex . This approach helps identify binding partners and functional protein complexes involved in ribosome biogenesis. IP experiments have been crucial in establishing the interactions between UTP4 and other components of the t-Utp subcomplex, such as Utp5, Utp8, Utp9, Utp10, Utp15, and Utp17 .

Western Blotting:
Western blotting with UTP4 antibodies provides quantitative assessment of UTP4 expression levels and can be used to verify the presence of wild-type versus mutant proteins . This approach is particularly valuable when studying the effects of mutations or depletion on protein stability and expression. In yeast studies, western blotting has confirmed that various C-terminal truncations of Utp4 affect protein stability differently, with some mutations leading to significant degradation .

Ribosome Biogenesis Assays:
UTP4 antibodies can be incorporated into experimental setups designed to investigate pre-rRNA processing, particularly when examining the effects of UTP4 mutations or depletion on 18S rRNA maturation . Research has shown that mutations in the C-terminus of UTP4, similar to the region affected in NAIC, cause substantial decreases in 18S rRNA levels, demonstrating the essential role of this region in ribosome biogenesis .

Chromatin Immunoprecipitation (ChIP):
Given UTP4's potential role as a transcriptional regulator , ChIP assays using UTP4 antibodies can help investigate its association with specific genomic regions, particularly rDNA. This application can provide insights into how UTP4 might directly influence transcription in addition to its role in RNA processing.

Advanced Research Questions

• How can UTP4 antibodies help investigate the role of UTP4 in ribosomal RNA processing disorders?

UTP4 antibodies serve as critical tools for investigating the pathophysiology of ribosomal RNA processing disorders, particularly those associated with UTP4 dysfunction such as North American Indian childhood cirrhosis (NAIC). These antibodies enable several sophisticated experimental approaches:

Mechanistic Investigation of Disease Mutations:
UTP4 antibodies can be employed to examine how disease-causing mutations, such as the R565W substitution in NAIC, affect UTP4's:

• Subcellular localization and nucleolar integration

• Protein-protein interactions within the SSU processome

• Association with pre-rRNA transcripts

• Stability and expression levels

Studies in yeast have shown that mutations in the C-terminus of Utp4, similar to the region affected in NAIC, disrupt ribosome biogenesis and cell growth . UTP4 antibodies enable researchers to translate these findings to human systems by comparing wild-type and mutant UTP4 behaviors in patient-derived samples or model systems.

Experimental Approaches:

• Immunoprecipitation-based RNA Analysis:

  • UTP4 antibodies can be used to immunoprecipitate UTP4-containing complexes.

  • Associated RNAs can be extracted and analyzed by Northern blotting or RNA-seq to identify abnormalities in pre-rRNA processing.

  • This approach has revealed that truncations in the C-terminus of yeast Utp4 cause substantial decreases in 18S rRNA levels .

• Proximity Labeling Proteomics:

  • Combining UTP4 antibodies with proximity labeling techniques (BioID or APEX2) allows identification of the proximal protein neighborhood of wild-type versus mutant UTP4.

  • This approach can reveal altered protein interactions caused by disease mutations.

• Patient Tissue Analysis:

  • In liver biopsy samples from NAIC patients, UTP4 antibodies can be used for immunohistochemistry to assess alterations in UTP4 expression or localization.

  • Combined with markers of cellular stress or ribosome dysfunction, this can provide insights into disease progression mechanisms.

• CRISPR-engineered Disease Models:

  • UTP4 antibodies are essential for validating CRISPR-engineered cellular models harboring NAIC or other UTP4 mutations.

  • They enable verification of mutant protein expression and subsequent functional analysis.

Quantitative Analysis of Ribosome Biogenesis:

Research using yeast models has established a direct correlation between UTP4 C-terminal mutations and defects in 18S rRNA maturation . A similar quantitative approach can be applied to human systems:

This type of quantitative analysis, facilitated by UTP4 antibodies, allows researchers to correlate molecular defects with cellular phenotypes and potentially with disease severity.

• What are the optimal experimental approaches for studying UTP4's role in North American Indian childhood cirrhosis (NAIC)?

Investigating UTP4's role in North American Indian childhood cirrhosis (NAIC) requires a multifaceted approach combining genetic, biochemical, and cellular methods. The R565W mutation in UTP4/Cirhin has been identified as the causative mutation in NAIC , but the mechanisms linking this mutation to liver disease remain poorly understood. Here are optimal experimental approaches using UTP4 antibodies to elucidate these mechanisms:

1. Patient-Derived Cellular Models:

Primary Hepatocyte Culture:

• Isolate primary hepatocytes from liver biopsy samples of NAIC patients and controls.

• Use UTP4 antibodies to analyze UTP4 localization, expression, and interaction partners.

• Compare nucleolar morphology and pre-rRNA processing between patient and control cells.

iPSC-Derived Hepatocytes:

• Generate induced pluripotent stem cells (iPSCs) from NAIC patients and differentiate them into hepatocytes.

• Apply UTP4 antibodies in time-course studies to track UTP4 dynamics during hepatocyte differentiation and maturation.

• This approach allows for the study of disease progression in a developmentally relevant context.

2. Molecular and Biochemical Analysis:

Co-Immunoprecipitation Studies:

• Use UTP4 antibodies to perform co-IP experiments comparing wild-type and R565W mutant UTP4.

• Analyze protein-protein interactions, particularly focusing on the t-Utp subcomplex components (Utp5, Utp8, Utp9, Utp10, Utp15, and Utp17) .

• Mass spectrometry analysis of immunoprecipitated complexes can identify additional interaction partners and how they are affected by the NAIC mutation.

Ribosome Biogenesis Analysis:

• Employ UTP4 antibodies in sucrose gradient centrifugation experiments to isolate and analyze pre-ribosomal complexes.

• Northern blotting or RNA-seq of associated RNAs can reveal specific pre-rRNA processing defects.

• Quantify 18S rRNA maturation efficiency in control versus NAIC patient cells.

3. Advanced Imaging Techniques:

Live Cell Imaging:

• Use fluorescently tagged UTP4 constructs (wild-type and R565W) in combination with UTP4 antibodies for validation.

• Perform FRAP (Fluorescence Recovery After Photobleaching) to assess the dynamics of nucleolar association.

• Compare mobility and residency time of wild-type versus mutant UTP4 in the nucleolus.

Super-Resolution Microscopy:

• Apply super-resolution techniques (STORM, PALM, or STED) with UTP4 antibodies to precisely localize UTP4 within the nucleolar subcompartments.

• Compare the spatial organization of wild-type versus mutant UTP4 relative to other nucleolar components.

4. Functional Genomics Approaches:

CRISPR/Cas9 Disease Modeling:

• Generate isogenic cell lines carrying the R565W mutation in UTP4.

• Use UTP4 antibodies to validate the models and analyze phenotypic changes.

• This approach controls for genetic background effects that may confound patient-derived samples.

Rescue Experiments:

• In UTP4-depleted cells, introduce either wild-type or R565W mutant UTP4 and use antibodies to confirm expression.

• Assess restoration of normal ribosome biogenesis and cell function.

• These experiments can directly test the causal relationship between the mutation and cellular phenotypes.

Experimental Data Comparison Table:

• How do results from UTP4 antibody experiments in different model systems compare?

Comparative analysis of UTP4 antibody experiments across different model systems provides valuable insights into both conserved functions and species-specific aspects of UTP4 biology. Understanding these similarities and differences is crucial for translating findings between model organisms and human disease contexts.

Cross-Species Comparison of UTP4 Structure and Function:

Experimental Results Comparison:

• Human cells: UTP4 antibodies typically reveal concentrated nucleolar staining with some nucleoplasmic signal.

• Yeast cells: Tagged Utp4 shows strong nucleolar concentration with minimal extra-nucleolar distribution.

2. Protein-Protein Interaction Networks:
Research using co-immunoprecipitation with UTP4 antibodies reveals both conserved and divergent interaction partners:

• Conserved interactions: Core components of the t-Utp subcomplex (Utp5, Utp8, Utp9) are identified as UTP4 interactors across species .

• Species-specific interactions: Human UTP4 has been reported to interact with HIVEP1, involved in viral promoter regulation - an interaction not reported in yeast.

3. Functional Impact of Mutations:
Studies of the NAIC-associated R565W mutation in human UTP4 compared with analogous mutations in model organisms:

• Human cells: Limited published data on direct effects of the R565W mutation on human cells.

• Yeast model: The homologous region in yeast Utp4 is essential for function, but the exact NAIC mutation does not produce the same phenotype in yeast, suggesting species-specific functional differences .

4. rRNA Processing Analysis:
Quantitative comparison of pre-rRNA processing defects:

Translation of Model System Findings to Human Disease:

• Using multiple model systems to validate findings

• Carefully interpreting results when translating between species

• Developing human cell-based models for studying NAIC and related disorders

By systematically comparing UTP4 antibody experiments across different model systems, researchers can identify conserved fundamental mechanisms of ribosome biogenesis while also recognizing species-specific aspects that may be particularly relevant to human disease.

• What are the challenges in generating specific antibodies against UTP4 and how can they be overcome?

Generating highly specific antibodies against UTP4/Cirhin presents several technical challenges due to its biochemical properties, conservation across species, and functional context. Understanding these challenges and implementing strategic approaches can significantly improve the development of research-grade UTP4 antibodies.

Major Challenges in UTP4 Antibody Generation:

1. Protein Structure and Accessibility:

• UTP4 contains WD40 repeat domains which form complex tertiary structures with limited surface-exposed unique epitopes.

• The functional C-terminal region implicated in NAIC may have conformational states that are difficult to replicate with peptide immunogens.

2. Nucleolar Localization:

• UTP4's nucleolar localization means it exists in dense macromolecular complexes, potentially masking epitopes in native conditions.

• Antibodies must recognize UTP4 within the context of the SSU processome complex.

3. Cross-Reactivity Concerns:

• UTP4 shares structural features with other WD40 repeat-containing proteins, increasing the risk of cross-reactivity.

• Distinguishing between UTP4 and its closely related family members requires highly selective antibodies.

4. Species Conservation Challenges:

• While UTP4 is conserved functionally across species, there are significant sequence differences , complicating the development of cross-species reactive antibodies.

• The limited sequence conservation between human and yeast orthologs makes it difficult to develop antibodies that work across diverse model systems.

Strategic Approaches to Overcome These Challenges:

1. Advanced Immunogen Design:

For UTP4, an effective approach would be to use a combination of:

• N-terminal domain (aa 1-100) recombinant fragments, as used in some commercial antibodies

• C-terminal peptides containing the region surrounding the NAIC mutation (R565)

• Structurally exposed loop regions identified through protein modeling

2. Advanced Antibody Generation and Screening Technologies:

Phage Display Selection Strategy:
Recent advances in antibody engineering allow for the selection of highly specific antibodies through iterative rounds of phage display . For UTP4, this approach could include:

• Sequential negative selection against related WD40 proteins to remove cross-reactive antibodies

• Positive selection using recombinant UTP4 under native conditions

• Additional screening against UTP4 in cellular contexts

Biophysics-informed Models for Specificity:
As described in search result , biophysics-informed modeling can be applied to identify antibody variants with customized specificity profiles:

• Training machine learning models on experimentally selected antibodies

• Identifying distinct binding modes associated with UTP4 versus potential cross-reactive antigens

• Generating antibody variants with enhanced specificity for UTP4

• How can UTP4 antibodies be validated for specificity in complex experimental designs?

Validating UTP4 antibodies for specificity is critical, especially in complex experimental designs investigating ribosome biogenesis disorders or nucleolar functions. A comprehensive validation strategy ensures reliable results and prevents misinterpretation of data due to antibody cross-reactivity or non-specific binding.

Multi-tiered Validation Framework for UTP4 Antibodies:

1. Molecular Validation Using Genetic Controls:

CRISPR/Cas9 Knockouts and Knockdowns:

• Generate complete UTP4 knockout cell lines using CRISPR/Cas9 genome editing.

• Create inducible knockdown systems using shRNA or siRNA targeting UTP4.

• These genetic controls provide the gold standard for antibody validation, as the target protein is absent or significantly reduced.

Example Validation Data:

Epitope Tagging Strategies:

• Express epitope-tagged UTP4 (HA, FLAG, or GFP) in cells.

• Perform parallel detection with both UTP4 antibody and tag-specific antibody.

• Colocalization confirms UTP4 antibody specificity.

2. Biochemical Validation Methods:

Peptide Competition Assays:

• Pre-incubate UTP4 antibody with excess immunizing peptide before application.

• Specific signals should be blocked by peptide competition.

• Non-specific signals will remain unaffected.

Immunoprecipitation-Mass Spectrometry:

• Perform IP with UTP4 antibody followed by mass spectrometry analysis.

• UTP4 should be among the most abundant proteins in the precipitate.

• Known UTP4 interactors from the t-Utp subcomplex (Utp5, Utp8, Utp9) should also be detected.

3. Cell and Tissue-Based Validation:

Subcellular Localization Validation:

• UTP4 antibodies should primarily detect nucleolar signals .

• Co-staining with established nucleolar markers (fibrillarin, nucleolin) should show significant overlap.

• Patterns should be consistent with UTP4's role in the SSU processome.

Tissue Expression Pattern Analysis:

• Compare UTP4 antibody staining patterns across multiple tissues with known UTP4 expression levels.

• Higher expression is expected in tissues with high protein synthesis rates.

• Liver tissue is particularly important given UTP4's association with NAIC .

4. Functional Validation in Complex Experimental Designs:

Chromatin Immunoprecipitation (ChIP) Validation:

• For experiments studying UTP4's role in transcriptional regulation .

• Include IgG controls and UTP4-depleted samples as essential negative controls.

• Confirm enrichment at known rDNA promoter regions.

Polysome Profiling Validation:

• For experiments investigating ribosome biogenesis.

• Confirm UTP4 antibody detection in pre-ribosomal fractions but not mature ribosome fractions.

• Verify altered profiles in UTP4 mutant conditions.

NAIC Mutation Studies:

• When studying the R565W mutation, confirm antibody recognition of both wild-type and mutant UTP4.

• Some epitope-specific antibodies may have altered affinity for the mutant protein.

By implementing this comprehensive validation framework, researchers can ensure that UTP4 antibodies perform with high specificity in complex experimental designs, providing reliable data for investigating ribosome biogenesis, nucleolar functions, and the molecular mechanisms underlying NAIC and related disorders.